Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis

Chee Yean Loo, Mohd Shahrir Mohamed Said, Rozita Mohd, Abdul Halim Abdul Gafor, Rashidi Saidin, Norma Abdul Halim, Mei Kwi Chua, Norella C T Kong

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This was a prospective randomized controlled trial to evaluate the effects of immunoadsorption (IA) versus conventional PP (PP) as adjunctive therapy in the treatment of severe lupus nephritis (LN).Of 28 patients with biopsy-proven severe LN (ISN/RPS classes III or IV ± V), 14 underwent 36 sessions of PP and the other 41 sessions of IA in addition to our center's standard LN treatment protocol. Three patients in the PP group and 2 in the IA group experienced a transient, marked drop in platelets with the second session. Except for a higher pre treatment mean SLEDAI score in the PP group 17.4 ± 2.0 vs. 13.5 ± 4.8; p= 0.009 and a serum creatinine of 163 ± 7.9 vs. 81.7 ± 10.2; p= 0.33, there were no other baseline differences. Some differences did exist between the two therapies in the immediate post-treatment phase, at 1 and 3. months. Three in IA relapsed, none of PP in third months, whereas two patients relapsed in the PP and none of IA cohorts at 6. months. However, most of these parameters did not differ by 6. months. The pre- and post-therapy SLEDAI scores remained different 12.4 ± 4.5 vs. 9 ± 4; p= 0.04 at 1. month, and at 3. month 13.5 ± 4.7 vs. 7.7 ± 1.1; p= 0.012 but not at 6. months.We conclude that IA and PP were equally well tolerated and efficacious as adjunctive therapy for severe LN.

Original languageEnglish
Pages (from-to)335-340
Number of pages6
JournalTransfusion and Apheresis Science
Volume43
Issue number3
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Lupus Nephritis
Plasmapheresis
Therapeutics
Clinical Protocols
Creatinine
Blood Platelets
Randomized Controlled Trials
Biopsy
Serum

Keywords

  • IA
  • PP
  • Severe lupus nephritis
  • SLEDAI score

ASJC Scopus subject areas

  • Hematology

Cite this

Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis. / Loo, Chee Yean; Mohamed Said, Mohd Shahrir; Mohd, Rozita; Abdul Gafor, Abdul Halim; Saidin, Rashidi; Halim, Norma Abdul; Chua, Mei Kwi; Kong, Norella C T.

In: Transfusion and Apheresis Science, Vol. 43, No. 3, 12.2010, p. 335-340.

Research output: Contribution to journalArticle

@article{7bcc0c6e86734db0941a94394e6b9501,
title = "Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis",
abstract = "This was a prospective randomized controlled trial to evaluate the effects of immunoadsorption (IA) versus conventional PP (PP) as adjunctive therapy in the treatment of severe lupus nephritis (LN).Of 28 patients with biopsy-proven severe LN (ISN/RPS classes III or IV ± V), 14 underwent 36 sessions of PP and the other 41 sessions of IA in addition to our center's standard LN treatment protocol. Three patients in the PP group and 2 in the IA group experienced a transient, marked drop in platelets with the second session. Except for a higher pre treatment mean SLEDAI score in the PP group 17.4 ± 2.0 vs. 13.5 ± 4.8; p= 0.009 and a serum creatinine of 163 ± 7.9 vs. 81.7 ± 10.2; p= 0.33, there were no other baseline differences. Some differences did exist between the two therapies in the immediate post-treatment phase, at 1 and 3. months. Three in IA relapsed, none of PP in third months, whereas two patients relapsed in the PP and none of IA cohorts at 6. months. However, most of these parameters did not differ by 6. months. The pre- and post-therapy SLEDAI scores remained different 12.4 ± 4.5 vs. 9 ± 4; p= 0.04 at 1. month, and at 3. month 13.5 ± 4.7 vs. 7.7 ± 1.1; p= 0.012 but not at 6. months.We conclude that IA and PP were equally well tolerated and efficacious as adjunctive therapy for severe LN.",
keywords = "IA, PP, Severe lupus nephritis, SLEDAI score",
author = "Loo, {Chee Yean} and {Mohamed Said}, {Mohd Shahrir} and Rozita Mohd and {Abdul Gafor}, {Abdul Halim} and Rashidi Saidin and Halim, {Norma Abdul} and Chua, {Mei Kwi} and Kong, {Norella C T}",
year = "2010",
month = "12",
doi = "10.1016/j.transci.2010.10.003",
language = "English",
volume = "43",
pages = "335--340",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis

AU - Loo, Chee Yean

AU - Mohamed Said, Mohd Shahrir

AU - Mohd, Rozita

AU - Abdul Gafor, Abdul Halim

AU - Saidin, Rashidi

AU - Halim, Norma Abdul

AU - Chua, Mei Kwi

AU - Kong, Norella C T

PY - 2010/12

Y1 - 2010/12

N2 - This was a prospective randomized controlled trial to evaluate the effects of immunoadsorption (IA) versus conventional PP (PP) as adjunctive therapy in the treatment of severe lupus nephritis (LN).Of 28 patients with biopsy-proven severe LN (ISN/RPS classes III or IV ± V), 14 underwent 36 sessions of PP and the other 41 sessions of IA in addition to our center's standard LN treatment protocol. Three patients in the PP group and 2 in the IA group experienced a transient, marked drop in platelets with the second session. Except for a higher pre treatment mean SLEDAI score in the PP group 17.4 ± 2.0 vs. 13.5 ± 4.8; p= 0.009 and a serum creatinine of 163 ± 7.9 vs. 81.7 ± 10.2; p= 0.33, there were no other baseline differences. Some differences did exist between the two therapies in the immediate post-treatment phase, at 1 and 3. months. Three in IA relapsed, none of PP in third months, whereas two patients relapsed in the PP and none of IA cohorts at 6. months. However, most of these parameters did not differ by 6. months. The pre- and post-therapy SLEDAI scores remained different 12.4 ± 4.5 vs. 9 ± 4; p= 0.04 at 1. month, and at 3. month 13.5 ± 4.7 vs. 7.7 ± 1.1; p= 0.012 but not at 6. months.We conclude that IA and PP were equally well tolerated and efficacious as adjunctive therapy for severe LN.

AB - This was a prospective randomized controlled trial to evaluate the effects of immunoadsorption (IA) versus conventional PP (PP) as adjunctive therapy in the treatment of severe lupus nephritis (LN).Of 28 patients with biopsy-proven severe LN (ISN/RPS classes III or IV ± V), 14 underwent 36 sessions of PP and the other 41 sessions of IA in addition to our center's standard LN treatment protocol. Three patients in the PP group and 2 in the IA group experienced a transient, marked drop in platelets with the second session. Except for a higher pre treatment mean SLEDAI score in the PP group 17.4 ± 2.0 vs. 13.5 ± 4.8; p= 0.009 and a serum creatinine of 163 ± 7.9 vs. 81.7 ± 10.2; p= 0.33, there were no other baseline differences. Some differences did exist between the two therapies in the immediate post-treatment phase, at 1 and 3. months. Three in IA relapsed, none of PP in third months, whereas two patients relapsed in the PP and none of IA cohorts at 6. months. However, most of these parameters did not differ by 6. months. The pre- and post-therapy SLEDAI scores remained different 12.4 ± 4.5 vs. 9 ± 4; p= 0.04 at 1. month, and at 3. month 13.5 ± 4.7 vs. 7.7 ± 1.1; p= 0.012 but not at 6. months.We conclude that IA and PP were equally well tolerated and efficacious as adjunctive therapy for severe LN.

KW - IA

KW - PP

KW - Severe lupus nephritis

KW - SLEDAI score

UR - http://www.scopus.com/inward/record.url?scp=78649472950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649472950&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2010.10.003

DO - 10.1016/j.transci.2010.10.003

M3 - Article

C2 - 21051293

AN - SCOPUS:78649472950

VL - 43

SP - 335

EP - 340

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 3

ER -